Salvadori M, Bertoni E (2013) Is it time to give up with calcineurin inhibitors in kidney transplantation? World J Transplant 3:7

Article  PubMed  PubMed Central  Google Scholar 

Knops N, Levtchenko E, van den Heuvel B, Kuypers D (2013) From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. Int J Pharm 452:14–35

Article  CAS  PubMed  Google Scholar 

Kumar J, Bridson JM, Sharma A, Halawa A (2017) Systematic review on role of mammalian target of rapamycin inhibitors as an alternative to calcineurin inhibitors in renal transplant: challenges and window to excel. Exp Clin Transplant 15:241–252

PubMed  Google Scholar 

Hernández D, Hernández D, Martínez D, Martínez D, Gutiérrez E, Gutiérrez E et al (2011) Clinical evidence on the use of anti-mTOR drugs in renal transplantation. Nefrología (English Edition) 31:27–34

Google Scholar 

Li C, Yang CW (2009) The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 5:513–519

Article  CAS  PubMed  Google Scholar 

Flechner SM (2009) Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors. Transplantation 87:S1–S6

Article  CAS  PubMed  Google Scholar 

Lodhi S, Lamb K, Meier-Kriesche HU (2011) Improving long-term outcomes for transplant patients: Making the case for long-term disease-specific and multidisciplinary research. Am J Transplant 11:2264–2265

Article  CAS  PubMed  Google Scholar 

Gullestad L, Iversen M, Mortensen S-A, Eiskjær H, Riise GC, Mared L et al (2010) Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 89:864–872

Article  CAS  PubMed  Google Scholar 

Serre J-E, Michonneau D, Bachy E, Noël L-H, Dubois V, Suberbielle C et al (2014) Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. Kidney Int 85:182–190

Article  CAS  PubMed  Google Scholar 

Gonzalez-Vilchez F, de Prada JV, Paniagua M, Gomez-Bueno M, Arizon J, Almenar L et al (2014) Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization? Int J Cardiol 171:15–23

Article  CAS  PubMed  Google Scholar 

Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A (2013) Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol 2013:1–13

Article  Google Scholar 

Peddi VR, Wiseman A, Chavin K, Slakey D (2013) Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transplant Rev 27:97–107

Article  Google Scholar 

Rostaing L, Kamar N (2010) mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol 23:133–142

CAS  PubMed  Google Scholar 

Ganschow R, Pape L, Sturm E, Bauer J, Melter M, Gerner P et al (2013) Growing experience with m TOR inhibitors in pediatric solid organ transplantation. Pediatr Transplant 17:694–706

Article  CAS  PubMed  Google Scholar 

Weir MR, Mulgaonkar S, Chan L, Shidban H, Waid TH, Preston D et al (2011) Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 79:897–907

Article  CAS  PubMed  Google Scholar 

Mjörnstedt L, Sørensen SS, von Zur Mühlen B, Jespersen B, Hansen J, Bistrup C et al (2012) Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. Am J Transplant 12:2744–2753

Article  PubMed  Google Scholar 

Heilman RL, Younan K, Wadei HM, Mai ML, Reddy KS, Chakkera HA et al (2011) Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. Transplantation 92:767–773

Article  CAS  PubMed  Google Scholar 

Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U et al (2011) Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377:837–847

Article  CAS  PubMed  Google Scholar 

Guba M, Pratschke J, Hugo C, Krämer BK, Nohr-Westphal C, Brockmann J et al (2010) Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation 90:175–183

Article  CAS  PubMed  Google Scholar 

Cibrik D, Silva HT Jr, Vathsala A, Lackova E, Cornu-Artis C, Walker RG et al (2013) Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 95:933–942

Article  CAS  PubMed  Google Scholar 

Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y et al (2018) Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol 29:1979–1991

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoy MJ et al (2022) Structure-guided synthesis of FK506 and FK520 analogs with increased selectivity exhibit in vivo therapeutic efficacy against cryptococcus. MBio 13(3):e0104922

Article  PubMed  Google Scholar 

Lee YR et al (2005) Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 105(10):3951–3955

Article  CAS  PubMed  Google Scholar 

Shityakov S et al (2017) In silico investigation of propofol binding sites in human serum albumin using explicit and implicit solvation models. Comput Biol Chem 70:191–197

Article  CAS  PubMed  Google Scholar 

Shityakov S et al (2020) Novel approach for characterizing propofol binding affinities to serum albumins from different species. ACS Omega 5(40):25543–25551

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sarukhanyan E et al (2019) Rational drug design of Axl tyrosine kinase type i inhibitors as promising candidates against cancer. Front Chem 7:920

Article  ADS  CAS  PubMed  Google Scholar 

Shityakov S et al (2021) Scaffold searching of FDA and EMA-approved drugs identifies lead candidates for drug repurposing in Alzheimer’s disease. Front Chem 9:736509

Article  CAS  PubMed  PubMed Central  Google Scholar 

Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, Onufriev A, Simmerling C, Wang B, Woods RJ (2005) The Amber biomolecular simulation programs. J Comput Chem 26:1668–1688

Galvelis R et al (2019) A scalable molecular force field parameterization method based on density functional theory and quantum-level machine learning. J Chem Inf Model 59(8):3485–3493

Article  CAS  PubMed  Google Scholar 

Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG (1995) A smooth particle mesh Ewald method. J Chem Phys 103:8577–8593

Article  ADS  CAS  Google Scholar 

Miyamoto S, Kollman PA (1992) Settle: an analytical version of the SHAKE and RATTLE algorithm for rigid water models. J Comput Chem 13:952–962

Article  CAS  Google Scholar 

Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L et al (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33:889–897

Article  CAS  PubMed  Google Scholar 

Diekmann F, Campistol JM (2015) Practical considerations for the use of mTOR inhibitors. Transplant Res 4(Suppl 1):5

PubMed  PubMed Central  Google Scholar 

Sutherland AI, Akhtar MZ, Zilvetti M, Brockmann J, Ruse S, Fuggle SV et al (2014) Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study. Am J Transpl 14(3):677–684

Article  CAS  Google Scholar 

Legaz I et al (2021) PCR array technology in biopsy samples identifies up-regulated mTOR Pathway genes as potential rejection biomarkers after kidney transplantation. Front Med (Lausanne) 8:547849

Article  PubMed  Google Scholar 

Gohlke H, Case DA (2004) Converging free energy estimates: MM-PB(GB)SA studies on the protein-protein complex Ras-Raf. J Comput Chem 25(2):238–250

Article  CAS  PubMed  Google Scholar 

Silva H Jr, Felipe CR, Garcia V, Neto E, Filho M, Contieri F et al (2013) Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. Am J Transplant 13:3155–3163

Article  CAS  PubMed  Google Scholar 

Groetzner J, Kaczmarek I, Schulz U, Stegemann E, Kaiser K, Wittwer T et al (2009) Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation 87:726–733

Article  CAS  PubMed  Google Scholar